May 15, 2026 Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
May 15, 2026 Blackbaud’s Latest Product Innovations Reflect Company’s Defensible Market Position; Anchored in Data, Context, and Trust
May 15, 2026 FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit with the Schall Law Firm
